Agios Pharmaceuticals (AGIO) EBIT (2016 - 2025)
Historic EBIT for Agios Pharmaceuticals (AGIO) over the last 14 years, with Q4 2025 value amounting to -$121.6 million.
- Agios Pharmaceuticals' EBIT rose 276.64% to -$121.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$472.1 million, marking a year-over-year decrease of 1089.76%. This contributed to the annual value of -$472.1 million for FY2025, which is 1089.76% down from last year.
- According to the latest figures from Q4 2025, Agios Pharmaceuticals' EBIT is -$121.6 million, which was up 276.64% from -$116.9 million recorded in Q3 2025.
- Agios Pharmaceuticals' 5-year EBIT high stood at -$90.6 million for Q1 2023, and its period low was -$127.1 million during Q2 2025.
- Over the past 5 years, Agios Pharmaceuticals' median EBIT value was -$101.0 million (recorded in 2022), while the average stood at -$102.8 million.
- Per our database at Business Quant, Agios Pharmaceuticals' EBIT plummeted by 11118.96% in 2021 and then surged by 1041.28% in 2023.
- Over the past 5 years, Agios Pharmaceuticals' EBIT (Quarter) stood at -$104.8 million in 2021, then increased by 5.39% to -$99.2 million in 2022, then dropped by 7.16% to -$106.3 million in 2023, then fell by 17.65% to -$125.0 million in 2024, then grew by 2.77% to -$121.6 million in 2025.
- Its EBIT stands at -$121.6 million for Q4 2025, versus -$116.9 million for Q3 2025 and -$127.1 million for Q2 2025.